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Abstract
Bovine mammary epithelial (BME-UV1, clone E-T and BME-UV, clone E-T2) and myoepithelial (BMM-UV, clone m-T2)
cell lines were used to study the modulation of cell-associated activity of urokinase-type plasminogen activator (u-PA), as
well as mRNA transcripts of u-PA, its receptor (u-PAR), and inhibitors (PAI-1 and PAI-2) during the cell cycle. After release
from a growth arrest accomplished by growth factor deprivation, the length of the cell cycle was determined as 19^21 h, with
G1, S, and G2+M phases of 6^7, 7^9, and 5^6 h respectively. As the cell cycle progressed, accumulated cell-associated u-PA
activity increased. Maximal activity occurred at the S/G2 boundary and decreased during the G2/M phases. All cell lines
tested produced plasmin-specific inhibitor(s). Accumulation of u-PA mRNA peaked 3 h after stimulation into the growth
cycle for m-T2 and E-T and during 3^6 h for E-T2 cells. Maximum levels of u-PAR mRNA were observed at 3 h for the E-T
cell line, 6^9 h for E-T2 cells, and 3^9 h for m-T2 cells. The cell cycle distribution of the PAI-1 mRNA was similar to that of
u-PA for both epithelial cell lines, while for m-T2 cells maximal accumulation of PAI-1 mRNA was detected at 3^9 h after
growth initiation. The increase of PAI-2 mRNA transcription for m-T2 and E-T cells was detected at 3^6 h. The PAI-2
mRNA in E-T2 cells was under detectable levels. The data indicate that the expression of the constituents of the PA system in
bovine mammary epithelial and myoepithelial cells is not cell type-dependent but is tightly connected to the phase of the cell
cycle. z 1998 Elsevier Science B.V.
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1. Introduction
Urokinase-type plasminogen activator (u-PA) is a
speci¢c serine protease expressed by many mamma-
lian cells [1]. While its major feature is to convert
inactive plasminogen into the active enzyme, plasmin
[2,3], u-PA can also directly degrade some extracel-
lular matrix proteins [4]. Plasmin, which is also a
serine protease with a broader spectrum of speci¢city
than that of u-PA, can degrade the extracellular ma-
trix directly or indirectly by activating a broad range
of latent metalloproteinases [5]. Signi¢cant attention
has been paid to plasminogen activators because of
their importance in a wide variety of biological proc-
esses including tissue remodeling, wound healing, cell
migration, tumor invasion and metastasis, and ex-
tracellular matrix turnover (for review see [2,3,5,6]).
It is widely accepted that the production of u-PA is
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regulated by growth factors [7,8], hormones [9,10],
extracellular matrix proteins [10], retinoic acid [11],
and even some bacterial products [12,13]. The activ-
ity of u-PA in vivo is directed and controlled by a
speci¢c u-PA receptor (u-PAR) and by a network of
PA-speci¢c inhibitors including PAI-1, PAI-2, pro-
tease nexin (PN-1), and PAI-3 (protein C inhibitor).
u-PAR expression in di¡erent cell types is also highly
regulated in a manner similar to that of u-PA [14].
As is the case with PA and u-PAR, the PAI are
secreted by speci¢c cell types in a highly regulated
manner and were found to be expressed at invasive
foci in many types of tumors as well as by di¡erent
normal and established cell types [15]. Finally, plas-
min activity is also modulated by numerous plasmin-
speci¢c inhibitors (K2-antiplasmin, K2-macroglobulin,
protease nexin, and urinary trypsin inhibitor/biku-
nin) synthesized by the liver and other tissues
[1,5,6,16]. Since the PA/plasminogen system is impli-
cated in a variety of basic biological processes, the
physiological, biochemical, enzymological, and bio-
physical characteristics of the di¡erent components
of this system have been extensively studied during
the last decade.
Less attention has been given to the role of the
plasminogen activator system during the cell cycle.
Recently, Ryan et al. [16] have reported that in
synchronized normal rat kidney cells, accumulation
of PAI-1 transcript peaked in mid-G1 phase and de-
clined during the S phase of the cell cycle. Similar
regulation of PAI-1 mRNA transcription has been
shown for synchronized human epidermal keratino-
cytes [17]. Orfanoudakis et al. [18] and Aggeler et
al.[19], using di¡erent cell models, found that the
highest level of cell-associated PA activity occurred
during S/G2 transition and was greatly reduced dur-
ing G2/M. This suggests that PA may be involved in
DNA replication and/or cell division. To our knowl-
edge, no comprehensive studies have investigated the
kinetics of cell cycle-dependent changes in PA activ-
ity along with modulation of corresponding mRNA
transcripts.
We have previously reported that bovine mam-
mary cells in culture express u-PA, u-PAR, and
PAI-1 [20,21]. Here we demonstrate that the modu-
lation of the expression of the components of the PA
system in bovine mammary epithelial and myoepithe-
lial cells is independent of cell type but is closely
related to a speci¢c stage of the cell cycle. We also
provide data indicating that as the cell cycle prog-
resses, plasmin-speci¢c inhibitor(s) may be as crit-
ically involved in the regulation of the PA/plasmino-
gen system as are PA inhibitors.
2. Materials and methods
2.1. Reagents
Cell culture media (DME-F12, RPMI 1640,
NCTC-135, DMEM), HBSS, lactose, lactalbumin
enzymatic hydrolysate, glutathione, L-ascorbic acid,
hydrocortisone, progesterone, gentamicin, penicillin/
streptomycin/neomycin, kanamycin, trypsin, cell dis-
sociation solution, Triton X-100, amiloride, D-Val-
Leu-Lys p-nitroanilide, human and bovine plasmino-
gen were purchased from Sigma. Bovine insulin,
transferrin, fetal bovine, newborn, and iron-supple-
mented calf sera (all heat-inactivated) were from Life
Technologies (Gibco BRL). Elastase (porcine pan-
creas) was purchased from Calbiochem-Novabio-
chem. Chromogenic substrate, Spectrozyme UK,
and u-PA standards were from American Diagnosti-
ca. Zeta-Probe GT nylon membranes were purchased
from BioRad. Bovine u-PA and u-PAR cDNA
probes were provided by Dr. J. Kra«tzschmar (Berlin,
Germany). Bovine PAI-1 cDNA was a kind gift from
Dr. M.S. Pepper (Geneva, Switzerland). Human
PAI-2 cDNA and genomic proliferating cell nuclear
antigen (PCNA) DNA were obtained from ATCC
(Rockville, MD; ATCC(R) 61352 and 61054). [K-
32P]dCTP and [methyl-3H]thymidine were purchased
from Amersham. Prime IT RmT Random Primer kit
was purchased from Stratagene.
2.2. Cells and culture conditions
Bovine mammary epithelial (BME-UV1, clone E-T
and BME-UV, clone E-T2) and myoepithelial
(BMM-UV, clone m-T2) cell lines were established
in our laboratory from primary culture developed
from a lactating mammary gland [22,23]. Cells within
200^250 population doublings (100^125 passages)
were employed. Epithelial cells were maintained in
combined DME-F12, RPMI 1640, and NCTC-135
(2:1:1) medium and myoepithelial cells were cultured
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in DM-F12, RPMI 1640, NCTC-135, and DMEM
(1:1:1:1) medium with di¡erent supplements as de-
scribed [23^25]. Myoepithelial cells were routinely
passaged using standard trypsin-EDTA (0.25% and
0.02% respectively) treatment while epithelial cells
were ¢rst treated with elastase (2.5 U/ml in non-en-
zymatic cell dissociation solution) for 5 min at 37‡C
followed by regular trypsin-EDTA treatment [24].
2.3. Determination of cell cycle phases
Growth of a subcon£uent cell layer in 24-well
plates was arrested by incubation in serum- and
growth factor/hormone-depleted medium for 24 h.
At the end of this period, cells were washed 3 times
with HBSS and renewed growth was stimulated by
addition of complete growth medium. Growth-stimu-
lated cells were pulse-labeled with [methyl-
3H]thymidine (5 WCi/ml) for 30 min. At indicated
time points cells were detached. Half of the cells
were used to determine [3H]thymidine incorporation
into DNA in terms of TCA precipitable radioactivity
as described elsewhere [25]. The other half were
counted using a hemocytometer. Each determination
was done in triplicate.
2.4. Preparation of cell lysate
In experiments performed to determine cell-associ-
ated PA activity, bovine mammary cells were grown
in 60 mm petri dishes and synchronized as described
above. At speci¢c times after the initiation of syn-
chronous growth, the cells were washed 3 times with
HBSS and harvested with a rubber policeman in the
presence of 0.1% Triton X-100, 0.05 M Tris-HCl,
0.15 M NaCl, pH 7.4. Cell lysates were vortexed
vigorously and stored at 320‡C. After centrifugation
at 5000Ug for 10 min, the supernatants were used
for the assays of PA and plasmin inhibitor activity.
Additionally, the number of viable cells at each time
point was determined by hemocytometry in the pres-
ence of Trypan blue.
2.5. Plasmin and plasminogen activator assay
PA activity in cell lysates was measured in tripli-
cate aliquots by an assay that uses di¡erent chromo-
genic substrates to discriminate between u-PA-specif-
ic plasminogen activation and direct u-PA
proteolytic (amidolytic) activity according to manu-
facturer recommendations. Plasmin activity gener-
ated in the presence of u-PA was monitored using
the substrate Val-Leu-Lys p-nitroanilide while Spec-
trozyme was used to detect u-PA activity. To explore
the possible presence of plasmin inhibitor(s), cell
lysates were preincubated with plasmin and the assay
was performed in the presence of plasmin-speci¢c
substrate. All assays were conducted at 37‡C in 96-
well plates as described [10]. u-PA activity was ex-
pressed as the increase in absorbance per 60 min at
V405 nm and ¢nally was normalized to the corre-
sponding cell number.
2.6. RNA extraction and Northern blot analysis
Subcon£uent monolayers of bovine mammary cells
grown in 100 mm petri dishes were treated as de-
scribed above. At speci¢c times after the initiation
of synchronous growth, total RNA extraction was
performed using a guanidinium thiocyanate isolation
procedure. Brie£y, culture medium was aspirated and
cells were lysed by the addition of 0.6 ml of solution
D. Cellular lysates were collected with a rubber po-
liceman and processed as described [26].
Total RNA (15 Wg) was fractionated on 1% agar-
ose gel in the presence of 2.0 M formaldehyde and
blot transferred to the membrane in 10USSC
(10USSC, 1.5 M NaCl, 0.15 M Na3Wcitrate, pH
7.0). Membranes were baked for 1 h at 80‡C and
subsequently UV-cross-linked. Blots were probed
with u-PA, u-PAR, PAI-1, PAI-2, and PCNA specif-
ic probes labeled with [K-32P]dCTP by the random
priming technique as recommended by the manufac-
turer. Ethidium bromide staining and 18S cDNA re-
probing were used as an internal loading and transfer
controls.
3. Results
3.1. Duration of cell cycle
Monolayer cultures of bovine mammary myoepi-
thelial (clone m-T2) and epithelial (clones E-T and E-
T2) cells were grown to approx. 25% con£uency,
after which the cells were synchronized in G0/G1 by
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incubation in medium without serum and growth
promoter supplements for 24 h. Preliminary experi-
ments (data not shown) have con¢rmed that under
these conditions approx. 95% of the cells are quies-
cent. After growth re-initiation, cells were pulse-la-
beled with [3H]thymidine, and thymidine incorpora-
tion and the corresponding cell numbers were
determined (Fig. 1). The classic pattern of the
progression of all three cell lines through the cell
cycle is apparent, with clearly distinguishable G1, S,
and G2/M phases of the cycle. The length of the
complete cell cycle is approx. 18 h (m-T2), 19.5 h
(E-T), and 21 h (E-T2), with G1, S and G2/M phases
comprising 6^7, 7^9, and 5^6 h respectively.
3.2. Accumulation of u-PA activity during cell cycle
progression
The lysates of cells synchronized throughout the
cell cycle showed a consistent increase in the level
of cell-associated u-PA proteolytic (amidolytic) activ-
ity, beginning immediately after growth stimulation
(Fig. 2). For all cell lines, the highest levels of activity
occur at the late S/early G2 stage of the cell cycle
followed by a decrease, primarily during the late M
phase. The relative accumulation of u-PA activity
increases from 100% in growth-arrested cells to
170% for m-T2 cell line (Fig. 2A), to 205% for E-T
(Fig. 2B), and to 255% for E-T2 (Fig. 2C) and then
decreases to 129%, 190%, and 186% correspondingly.
As expected, the relative accumulation increases
when the cells enter a new cell cycle. Despite the
distinct di¡erences in the absolute values (both max-
imal and minimal levels) of activity detected in di¡er-
ent cell lines, these data clearly indicate that the dis-
tribution of cell-associated u-PA activity within cell
cycle phases is not dependent on if it is epithelial or
myoepithelial cells but rather is closely associated
with the order of cell cycle progression. To eliminate
Fig. 2. Cell cycle-dependent appearance of cell-associated u-PA
amidolytic activity in m-T2 (A), E-T (B), and E-T2 (C) cell ly-
sates. Growth-arrested cells were stimulated with complete me-
dium and cell detergent extracts in triplicate were prepared at
the indicated times. U-PA activity was measured spectrophoto-
metrically using u-PA-speci¢c substrate. The data are expressed
as change in absorbance/h/105 cells, and are normalized to the
activity in quiescent cell extracts. The standard deviation of de-
tected activity did not exceed 10% per sample (n = 3).
Fig. 1. Synchronized [3H]thymidine incorporation by bovine
mammary cells. For each determination, m-T2 myoepithelial
(F), E-T (O) and E-T2 (U) epithelial cells were pulsed with
5 WCi/ml of [methyl-3H]thymidine for 30 min at 37‡C and har-
vested at the indicated times after growth stimulation. Acid pre-
cipitable radioactivity was measured by liquid scintillation de-
tector. Cells in parallel wells were used for determination of cell
number. The data are expressed as cpm per 100 cells and repre-
sent one of three similar experiments. The standard deviation
of the amount of [3H]thymidine incorporated did not exceed
10% per sample (n = 3).
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underestimation of detected u-PA activity (in order
to activate presumably existing scu-PA), cellular ly-
sates were treated with trace amounts (0.01 U/ml) of
plasmin followed by the direct assay in the presence
or absence of the plasmin inhibitor aprotinin. The
data (not presented) revealed that there is little or
no inactive u-PA in the cell lysates we used.
3.3. Detection of plasminogen activation activity
To further characterize the modulation of u-PA
activity, we tested the same cell lysates using an in-
direct PA assay which employs exogenously added
plasminogen and the plasmin-speci¢c chromogenic
substrate. Surprisingly, the time course of u-PA-spe-
ci¢c plasminogen activation activity did not re£ect
the dynamics of the u-PA amidolytic activity de-
scribed above. Furthermore, as observed in Fig. 3,
the appearance of u-PA-generated plasmin activity is
greatly reduced as cells traverse the G1 phase of the
cell cycle remaining, for the m-T2 myoepithelial cell
line (Fig. 3A), undetectable in S and G2 segments
with a rapid increase in the M phase and thereafter.
For the E-T2 epithelial cell line (Fig. 3C), the level of
plasmin activity detected was approximately halved
during S and G2/M phases as compared to quiescent
cells with a slight increase at the beginning of the
next cell cycle. Finally, the E-T epithelial cell line
lysates showed a 2-fold decrease in generated plasmin
activity during only the G1 phase of the cell cycle
Fig. 4. Kinetics of induction of plasmin inhibitors in growth-
stimulated m-T2 (A), E-T (B), and E-T2 (C) cells during cell
cycle progression. Samples of the same cell extracts as in Figs.
2 and 3 were preincubated with plasmin (0.25 U/ml) for 30 min
at 37‡C followed by chromogenic substrate assay with plasmin-
speci¢c substrate. The data are expressed as percentage of re-
covered activity from the activity of plasmin preincubated with
lysis bu¡er.
Fig. 3. Cell cycle regulation of PA activity in m-T2 (A), E-T
(B), and E-T2 (C) cell lysates. The same cell lysates as in Fig. 1
were analyzed for PA activity using indirect chromogenic sub-
strate assay in the presence of plasminogen and plasmin-speci¢c
substrate. The data were obtained and processed as in Fig. 2
and are expressed as percentage of the activity presented in cell
extracts at time 0.
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(Fig. 3B) with progressive increase during all subse-
quent stages.
3.4. Detection of plasmin inhibitor activity
In order to learn more about the involvement of
plasmin inhibitor(s) activity in the regulation of the
PA/plasminogen system during cell cycle progression,
we employed direct plasmin assay using the same
samples. This allows us to rule out any possible in-
£uence of PA inhibitors. In Fig. 4, it can be clearly
seen that even quiescent cell lysates contain substan-
ces capable of plasmin inhibition. Further decline in
plasmin activity detected occurs for all cell lines dur-
ing the G1 phase of the cell cycle. For the m-T2 cell
line (Fig. 4A), the 2-fold decrease persists during G1
and S phases followed by a 1.5-fold increase in
G2/M, and ¢nally approaches a steady-state level.
Similar results were observed for both epithelial cell
lines except a 4-fold inhibition of plasmin activity in
E-T cell lysates (Fig. 4B) persisted into early G2
phase while for the E-T2 cell line it was achieved
at late G1 phase of the cell cycle (Fig. 4C). These
results indicate that the inhibitory activity(ies) ob-
served in both plasminogen activator and plasmin
assays is mainly due to the presence of plasmin
inhibitor(s) rather than PA inhibitor(s).
3.5. Northern blot hybridization
Northern blot analysis was performed to evaluate
the modulation of u-PA, u-PAR, PAI-1 and PAI-2
mRNA transcripts during the cell cycle. Consistent
with the results of the u-PA-speci¢c amidolytic assay,
low u-PA mRNA levels were detected in quiescent
cells (Fig. 5A,B,C, lane 1). Increases in u-PA tran-
scription were rapid, attained maximal level in mid-
G1 phase (3 h post stimulation for m-T2 and E-T
cells and 3^6 h for the E-T2 cell line), and declined
with the onset of DNA synthesis. During G2/M
Fig. 6. Study of 1.4 kb u-PAR mRNA levels during the cell
cycle. After stripping, the same membranes as in Fig. 5 were re-
hybridized with labeled bovine u-PAR cDNA. The lane indica-
tions and autorad letters are the same as in Fig. 5.
Fig. 5. Time course for 2.3 kb u-PA mRNA synthesis during
the cell cycle. Growth-arrested cells were incubated for di¡erent
periods of time in complete medium. Total RNA was extracted,
subjected to agarose gel electrophoresis, transferred to mem-
brane, and hybridized with labeled bovine u-PA cDNA. (A) m-
T2 cells ; (B) E-T cells ; (C) E-T2 cells. Each numbered lane cor-
responds to: 1, 0 h; 2, 3 h; 3, 6 h; 4, 9 h; 5, 12 h; 6, 15 h; 7,
18 h; 8, 21 h; 9, 24 h; 10, 30 h.
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phases, the u-PA mRNA abundance approximated
that of growth-arrested cells.
Similar to u-PA transcripts, the u-PAR mRNA
levels were low in quiescent cells (Fig. 6A,B,C, lane
1) for all cell lines and increased signi¢cantly within
3 h of growth stimulation (Fig. 6, lane 2). Subsequent
kinetics of the u-PAR mRNA transcript accumula-
tion during the cell cycle were di¡erent from that of
u-PA and were unique for each cell line. For the E-T
epithelial cells, the u-PAR transcripts peaked at 3 h
but, unlike those of u-PA mRNA, continued to be
elevated at 6 and even 9 h after growth stimulation
(Fig. 6B). For the E-T2 epithelial cell line, the u-PAR
mRNA abundance peaked during 6 and 9 h, and
remained at the increased level even at 12 h (mid-S
phase) (Fig. 6C). For the m-T2 myoepithelial cells,
the maximal increase in u-PAR transcript levels seen
at 3 h (mid-G1) was maintained at the same levels
through 6 h (G1/S boundary) and 9 h (early S phase)
of the cell cycle (Fig. 6A). These results suggest
that as the cell cycle progresses, the increase in
u-PAR mRNA transcription is one step behind the
corresponding increase in u-PA mRNA transcrip-
tion.
As can be seen from Fig. 7, the cell cycle regula-
tion of PAI-1 mRNA transcription is very similar to
that of u-PA. Again, maximal accumulation of PAI-
1 mRNA in E-T and E-T2 cell lines occurred at 3 h
and 3^6 h after growth stimulation respectively (Fig.
7B,C). The m-T2 myoepithelial cells di¡ered some-
what in that the PAI-1 mRNA levels were equally
elevated from 3 to 9 h after initiation of growth cycle
(Fig. 7A) while u-PA transcript clearly peaked at 3 h
(Fig. 5A). The PAI-2 mRNA transcripts in quiescent
cells were at very low levels (Fig. 8). As expected,
growth stimulation triggered the increase in PAI-2
mRNA transcription. Maximal induction was de-
tected in early G1 phase of the cell cycle for m-T2
cells and during early/late G1 for E-T cells. We did
not ¢nd any detectable levels of PAI-2 transcripts in
the E-T2 cell line.
In order to ascertain cell cycle position, the mem-
branes were hybridized with a PCNA (a co-factor of
DNA polymerase N also known as cyclin) probe. In
agreement with a previous report [27], cyclin mRNA
expression was undetectable in growth-arrested cells.
Appearance of PCNA transcripts was ¢rst observed
during G1/S transition (Fig. 9), reached a maximum
during the S phase, and rapidly decreased at the end
of the S phase.
Taken collectively, these results raised the possibil-
ity that during the cell cycle the di¡erent components
Fig. 8. Regulation of steady-state 2.0 kb PAI-2 mRNA in the
cell cycle. The same membranes as in Figs. 5^7 were stripped
and reprobed with labeled human PAI-2 cDNA. The lane indi-
cations and autorad letters are the same as in Fig. 5.
Fig. 7. Regulation of steady-state 3.2 kb PAI-1 mRNA in the
cell cycle. The same membranes as in Figs. 5 and 6 were
stripped and reprobed with labeled bovine PAI-1 cDNA. The
lane indications and autorad letters are the same as in Fig. 5.
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of the PA system are regulated in a concerted man-
ner.
4. Discussion
In this study we investigated the cell cycle-speci¢c
variation of cell-associated u-PA activity and, in par-
allel, the expression of transcripts of u-PA and other
components of the PA system in established bovine
mammary epithelial and myoepithelial cell lines. Our
results demonstrate that the biosynthesis and appear-
ance of u-PA-speci¢c activity are highly regulated by
the stage of the cell cycle. Direct u-PA amidolytic
assay reveals that quiescent bovine mammary cells
start to increase steady-state levels of cell-associated
u-PA activity immediately after mitogenic stimula-
tion (Fig. 2) with maximal accumulation within the
late S/early G2 stage, falling during G2/M phase.
While the magnitude varied somewhat, all cell lines
showed a very similar pattern of the distribution of
PA activity in corresponding phases of the cell cycle.
Aggeler et al. [19] using ¢brinolytic assay found that
cell-associated PA peaked at the late S phase in Chi-
nese hamster ovary cells (CHO) with a great reduc-
tion during G2/M. Human alveolar epithelial cells
(A549) also produce high levels of PA at S/G2 tran-
sition [18], while rat hepatoma cells (ZHC) show
maximum cell-associated PA activity at the very be-
ginning of the S phase [19]. In these studies, however,
the accumulation of PA during the G1 phase was not
recorded.
Since the indirect PA assay in the presence of plas-
minogen is estimated to be 10^1000-fold more sensi-
tive than the direct assay, we used this test to reprobe
the same samples. Surprisingly, the results obtained
with indirect PA assay con£icted with the data from
direct PA assay. No increase in plasminogen activa-
tion activity was observed during the G1 phase of the
cell cycle that we anticipated because of the increase
in PA activity. On the contrary, we detected a strong
(40^100%) decrease of plasminogen activation as
compared to quiescent cell lysates. In addition, the
overall pro¢le of plasminogen activation was unique
for each cell line. Namely, the m-T2 myoepithelial
cells showed the greatest decrease during early G1,
falling to undetectable levels during S and G2 stages
with subsequent increase in M phase. The E-T epi-
thelial cells showed reduced (50% decrease) plasmi-
nogen activation activity only during G1 phase fol-
lowed by a constant increase thereafter. Finally, E-
T2 epithelial cells showed a decrease of plasminogen
activation through all phases of the cell cycle with
only a small increase as the next cycle began. These
results can only be explained by the presence of in-
creasing amounts of PA and/or plasmin inhibitors. In
this regard, the fact that the amidolytic activity of u-
PA detected in the direct PA assay was una¡ected
may indicate that the corresponding inhibitors are
present in non-active, or latent forms. Indeed, recent
structural studies on PAI-1 [28,29], PAI-2 [30,31],
and protein C inhibitor (PAI-3) [32] have shown
that these inhibitors occur in both active and latent
Fig. 9. Appearance of 1.3 kb PCNA mRNA in growth-stimu-
lated cells. The same membranes as in Figs. 5^8 were stripped
and reprobed with labeled human PCNA probe. The lane indi-
cations and autorad letters are the same as in Fig. 5. Bottom
panel represents control hybridization with 18S RNA-speci¢c
probe.
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conformations which may be activated by plasmin
generated from plasminogen in the presence of u-
PA. Furthermore, PAI-2 has been characterized as
a predominantly intracellular inhibitor whose phys-
iological intracellular function is as yet uncertain
[30,33]. Latent conformations of plasmin-speci¢c in-
hibitors which can be proteolytically activated have
also been described for K2-macroglobulin [34], inter-
K-trypsin inhibitor [35], and urinary trypsin inhibi-
tor/bikunin [36].
To separate the e¡ect of PAIs and plasmin inhib-
itors, we included a colorimetric assay in which ac-
tive plasmin was preincubated with the cell lysate
samples. If the activation of latent PAIs was a key
in£uence on the results of the indirect PA assay, the
direct plasmin assay would reveal no di¡erences in
recorded activity. However, plasmin assay showed
that for all cell lines tested the role of plasmin inhib-
itors is important at least during the G1 and S phases
(Fig. 4). According to our preliminary data (not
shown) one of these inhibitors is urinary trypsin in-
hibitor/bikunin. Further evaluation and quantitation
of the data obtained with all three cell lines reveal
that plasmin inhibitors play a central role in the PA/
plasminogen system regulation during the cell cycle.
This conclusion raises the question of the role of u-
PA in the progression through the cell cycle. If the
role is solely to activate plasminogen, then it would
be logical to control the very early steps of the am-
pli¢cation loop, i.e., plasminogen activation. This
seems not to be the case since, during G1 and S
phases of the cell cycle, cell-associated u-PA activity
progressively increases while u-PA-generated plasmin
activity is strongly suppressed. It is tempting to spec-
ulate that during cell cycle progression u-PA may
have targets other than plasminogen activation.
These might include the activation of other latent
proteases, plasmin-independent proteolytic process-
ing of other proteins including growth factor activa-
tion [37,38], or a direct function as a growth factor
due to the presence within the u-PA molecule of a
growth factor-like domain [39]. Interestingly, the de-
crease in plasmin inhibitory activity detected during
G2/M phases coincides with reduced levels of cell-
associated u-PA activity. Since others have described
an increased appearance of secreted PA in cell-con-
ditioned medium during this stage of the cell cycle
[19,40], it may be that mitotic cells use the PA/plas-
minogen system in order to disrupt their association
with the extracellular matrix allowing cell division.
On the basis of these results, it is constructive to
speculate that extracellular proteolysis during mitotic
division is mainly governed by secreted free u-PA
while focalized cell surface-associated u-PA is more
involved in pericellular proteolysis (or other activ-
ities) during the S phase of the cell cycle.
A second group of experiments provides intriguing
data. Based upon Northern blot hybridization, it can
be concluded that the maximum transcription of the
u-PA gene is restricted to a short ‘window’ in mid- to
late G1 phase (3^6 h after growth stimulation) of the
cell cycle (Fig. 5). The highest levels of cell-associated
u-PA activity, however, are found at S/G2 boundary
or early G2 stage (9^12 h later) when the u-PA
mRNA level is approximately that of quiescent cells.
The physiological signi¢cance of such a delay be-
tween maximal transcription and the appearance of
active protein is as yet unclear. In contrast, the
present study and earlier reports [27,41] showed
that the maximal expression of cell cycle-dependent
PCNA (both at mRNA and protein levels) occurs
during the S phase. Resembling the pattern of u-
PA mRNA appearance, the u-PAR, PAI-1, and
PAI-2 mRNA transcripts also peaked early in the
G1 phase. Similar cell cycle-dependent accumulation
of PAI-1 and PAI-2 transcripts (mid-G1 phase) has
been described in previous reports [16,17,42,43].
None of these studies, however, described the cell
cycle regulation of u-PA and u-PAR transcripts or
the modulation of u-PA activity. Since the majority
of total cell-associated u-PA in bovine mammary
cells is presented as membrane receptor-bound activ-
ity [21], the concurrent modulation of u-PA, u-PAR,
PAI-1, and PAI-2 should lead to the modulation of
detected extracellular u-PA activity during the cell
cycle. The delay between maximum transcription
and the maximum activity of cell-associated u-PA
may be due to posttranscriptional regulation. Alter-
natively, during initial stages of the cell cycle u-PA
(alone or complexed with PAIs and/or u-PAR) may
have non-proteolytic functions.
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